Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

2 papers

Acute Marijuana Effects on Human Risk Taking

Scott D. Lane, Don R. Cherek, Oleg V Tcheremissine, Lori M. Lieving, Cythia J Pietras
Neuropsychopharmacology Summary & key facts 2005 172 citations

Researchers gave 10 adults placebo cigarettes and three active marijuana cigarettes (including a 3.58% Delta9-THC dose) in a repeated-measures lab test. Using a task that forced a choice between a risky and a nonrisky option, the highest THC dose made people choose the risky option more often. The same high…

Cannabis and Cannabinoid Research Child and Adolescent Psychosocial and Emotional Development Substance Abuse Treatment and Outcomes

Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism

Jennifer Mitchell, B. Anderson
Neuropsychopharmacology Summary & key facts 2023 44 citations

This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.